A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia

Momelotinib is a potent inhibitor of JAK1 and JAK2 that demonstrated efficacy in patients with primary and secondary myelofibrosis. This phase 2, open-label, randomized study evaluated the efficacy and safety of oral once-daily momelotinib (100 mg and 200 mg) for the treatment of polycythemia vera (...

Descripción completa

Detalles Bibliográficos
Autores principales: Verstovsek, Srdan, Courby, Stephane, Griesshammer, Martin, Mesa, Ruben A., Brachmann, Carrie Baker, Kawashima, Jun, Maltzman, Julia D., Shao, Lixin, Xin, Yan, Huang, Daniel, Bajel, Ashish
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170698/
https://www.ncbi.nlm.nih.gov/pubmed/28622623
http://dx.doi.org/10.1016/j.leukres.2017.05.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170698/
https://www.ncbi.nlm.nih.gov/pubmed/28622623
http://dx.doi.org/10.1016/j.leukres.2017.05.002

Ejemplares similares